Ticker LaunchDirect listing · SLN
Silence Therapeutics plc
Silence Therapeutics plc (SLN) went public through a direct listing on Nasdaq Capital Market on Sep 8, 2020.
Silence Therapeutics plc is a biotechnology company discovering and developing molecules based on short interfering RNA (siRNA) that reduce production of disease-associated proteins by degrading specific messenger RNA. Its siRNA delivery system is designed to reach targeted cells in the liver.
- Status
- Direct listing
- Ticker
- SLN
- Exchange
- Nasdaq Capital Market
- Listed
- Sep 8, 2020
- First filed
- Aug 20, 2020
- Sector
- Biotech & pharma
More on this listing for subscribers
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Aug 20, 2020
- Latest amendment Aug 26, 2020
- Final prospectus (424B4) Sep 8, 2020
- All filings on EDGAR CIK 1479615
Other Biotech & pharma direct listings in 2020
- Pharming Group N.V.PHAR · Dec 23, 2020